Replimune Group, Inc. announced the appointment of Emily Hill as Chief Financial Officer (CFO). Ms. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and investor relations roles at several leading public biotechnology and pharmaceutical companies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.43 USD | -4.32% | +0.31% | -23.72% |
May. 16 | Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Apr. 08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.72% | 413M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer